| 词条 | Dopamine agonist |
| 释义 |
| Name = Dopamine receptor agonist | Use = Parkinson's disease, Attention deficit hyperactivity disorder, restless legs syndrome, clinical depression, etc. | Biological_target = Dopamine receptors | ATC_prefix = N04 | MeshID = D010300 }} A dopamine receptor agonist is a compound that activates dopamine receptors. Dopamine receptor agonists activate signaling pathways through trimeric G-proteins and β-arrestins, ultimately leading to changes in gene transcription. Today, for several dopamine receptor subtypes (D1, D2, D3) agonists are known, that differentially address these signalling pathways. They are called biased agonists.[1][2][3][4][4] UsesSome medical drugs act as dopamine agonists and can treat hypodopaminergic (low dopamine) conditions; they are typically used for treating Parkinson's disease (PD), Attention deficit hyperactivity disorder (in the form of stimulants) and certain pituitary tumors (prolactinoma), and may be useful for restless legs syndrome (RLS). Both ropinirole and pramipexole are FDA-approved for the treatment of RLS. There is also an ongoing clinical trial to test the effectiveness of the dopamine agonist ropinirole in reversing the symptoms of SSRI-induced sexual dysfunction.[5] Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF).[6] Side effectsSome of the common side effects of dopamine agonists include:[7][8]
ExamplesExamples of dopamine agonists include: Partial agonist
Agonists of full/unknown efficacy
Some, such as fenoldopam, are selective for dopamine receptor D1.[15] Indirect agonistsThere are two classes of drugs that act as indirect agonists of dopamine receptors: dopamine reuptake inhibitors and dopamine releasing agents. The most commonly prescribed indirect agonists of dopamine receptors include:
Other examples include:
See also
References1. ^{{cite journal |vauthors=Möller D, Banerjee A, Uzuneser TC, Skultety M, Huth T, Plouffe B, Hübner H, Alzheimer C, Friedland K, Müller CP, Bouvier M, Gmeiner P |title=Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure |journal=J. Med. Chem. |volume=60 |issue=7 |pages=2908–2929 |year=2017 |pmid=28248104 |doi=10.1021/acs.jmedchem.6b01857 |url=}} 2. ^{{cite journal |vauthors=Hübner H, Schellhorn T, Gienger M, Schaab C, Kaindl J, Leeb L, Clark T, Möller D, Gmeiner P |title=Structure-guided development of heterodimer-selective GPCR ligands |journal=Nat Commun |volume=7 |issue= |pages=12298 |year=2016 |pmid=27457610 |pmc=4963535 |doi=10.1038/ncomms12298 |url=}} 3. ^{{cite journal |vauthors=Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY, Smith AB, Kortagere S |title=Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists |journal=ACS Chem Neurosci |volume=8 |issue=3 |pages=486–500 |year=2017 |pmid=27801563 |pmc=5813806 |doi=10.1021/acschemneuro.6b00221 |url=}} 4. ^{{cite journal |vauthors=Park SM, Chen M, Schmerberg CM, Dulman RS, Rodriguiz RM, Caron MG, Jin J, Wetsel WC |title=Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice |journal=Neuropsychopharmacology |volume=41 |issue=3 |pages=704–15 |year=2016 |pmid=26129680 |pmc=4707817 |doi=10.1038/npp.2015.196 |url=}} 5. ^{{ClinicalTrialsGov|NCT00334048}} - "Treating Sexual Dysfunction From SSRI Medication: a Study Comparing Requip CR to Placebo" 6. ^{{cite journal |last1=Youssef |first1=Mohamed A.F.M. |last2=van Wely |first2=Madelon |last3=Hassan |first3=Mohamed Ahmed |last4=Al-Inany |first4=Hesham Gaber |last5=Mochtar |first5=Monique |last6=Khattab |first6=Sherif |last7=van der Veen |first7=Fulco |date=March 30, 2010 |title=Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis |url=https://academic.oup.com/humupd/article/16/5/459/664196/Can-dopamine-agonists-reduce-the-incidence-and |journal=Human Reproduction Update |volume=16 |issue=5 |pages=459–66 |pmid=20354100 |doi=10.1093/humupd/dmq006 |accessdate=September 28, 2017}} 7. ^{{cite web |url=https://medlineplus.gov/druginfo/meds/a697029.html |title=Pramipexole: MedlinePlus Drug Information |publisher=United States National Library of Medicine |accessdate=September 28, 2017}} 8. ^{{cite journal |last=Boyd |first=Alan |date=March 1995 |title=Bromocriptine and psychosis: A literature review |journal=Psychiatric Quarterly |volume=66 |issue=1 |pages=87–95 |doi=10.1007/BF02238717 |pmid=7701022 }} 9. ^{{cite journal |last=Yeung |first1=Eugene Y.H. |last2=Cavanna |first2=Andrea E. |date=September 1, 2014 |title=Sleep Attacks in Patients With Parkinson's Disease on Dopaminergic Medications: A Systematic Review |journal=Movement Disorderes Clinical Practice |volume=1 |issue=4 |pages=307–316 |doi=10.1002/mdc3.12063 |pmid=30363881 |pmc=6183021 }} 10. ^{{cite journal |last=Nirenberg |first=MJ |date=August 2013 |title=Dopamine agonist withdrawal syndrome: implications for patient care |journal=Drugs & Aging |volume=30 |issue=8 |pages=587–92 |pmid=23686524 |doi=10.1007/s40266-013-0090-z |accessdate=}} 11. ^Seeman P, Guan HC, Hirbec H (2009). "Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse 63 (8): 698–704. doi:10.1002/syn.20647. {{PMID|19391150}}. 12. ^1 {{cite journal |last1=Conroy |first1=JL |last2=Free |first2=RB |last3=Sibley |first3=DR |date=April 15, 2015 |title=Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor |journal=ACS Chemical Neuroscience |volume=6 |issue=4 |pages=681–92 |pmid=25660762 |pmc=5234767 |doi=10.1021/acschemneuro.5b00020 |accessdate=}} 13. ^FDA Announces Voluntary Withdrawal of Pergolide Products 14. ^{{cite journal |last1=Matera |first1=Carlo |last2=Quadri |first2=Marta |last3=Pelucchi |first3=Silvia |last4=Amici |first4=Marco De |last5=Dallanoce |first5=Clelia |date=April 17, 2014 |title=A convenient synthesis of 4-(2-hydroxyethyl)indolin-2-one, a useful intermediate for the preparation of both dopamine receptor agonists and protein kinase inhibitors |journal=Monatshefte für Chemie |volume=145 |issue=7 |pages=1139–1144 |doi=10.1007/s00706-014-1211-z |issn=0026-9247 }} 15. ^{{cite journal |last1=Ng |first1=Sylvia SW |last2=Pang |first2=Catherine CY |date=March 2000 |title=In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist |journal=British Journal of Pharmacology |volume=129 |issue=5 |pages=853–8 |pmid=10696081 |pmc=1571905 |doi=10.1038/sj.bjp.0703119}}
External links
1 : Dopamine agonists |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。